New hope for children with eye tumors, cancer

June 24, 2003

SAN FRANCISO - A deadly form of cancer in children, which starts out as a tumor in the eye, can now be treated successfully by a combination of therapies. This is the conclusion of a study appearing in the June issue of Ophthalmology, the clinical journal of the American Academy of Ophthalmology, the Eye M.D. Association.

Malignant retinal tumors in children, called retinoblastomas, which have spread to the bones, bone marrow and soft tissue can be successfully treated by a combination of high-dose chemotherapy, radiation therapy and transplantation of blood-producing stem cells.

In the study, conducted at St. Jude Children's Hospital in Memphis, Tennessee, four pediatric patients were treated with intensive chemotherapy - a combination of several very-high-dose anti-cancer drugs - radiation therapy, and the transplantation of the patients' own blood-producing stem cells. The blood stem cells were harvested after two to four courses of chemotherapy.

In all cases, the bone marrow disease went into complete remission after two courses of chemotherapy, which was followed by radiation and stem-cell therapy. Of the four patients, two survived free of disease longer than six years. In the other two patients, disease recurred in the central nervous system and they did not survive. Disease of the central nervous system continues to be the major obstacle to improved outcomes for patients with metastatic retinoblastomas.

Carlos Rodriguez-Galindo, MD, lead author of the study, said, "Our results show that retinal tumors that metastasize to other areas of the body can be cured. Chemotherapy by itself only results in transient improvement, with all patients dying of disease progression eventually, whereas chemotherapy in combination with radiation and stem-cell therapies can actually save patients' lives. We believe more than 90 percent of patients can be cured with surgery if the disease is detected early enough, before the disease spreads."

Dr. Rodriguez-Galindo and colleagues are working with Ira J. Dunkel, MD, at Memorial Sloan Kettering Cancer Center in New York and with Eric F. Grabowski, MD, ScD, at Massachusetts General Hospital for Children to develop a national protocol that will apply these principles of therapy to all children with this disease.

Based on data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (http://seer.cancer.gov), Dr. Rodriguez-Galindo estimates the number of annual retinoblastoma cases in the United States to be between 300 and 350. Of these, approximately 15, or five percent, develop retinal tumors that spread outside of the eye. "However," he said, "in developing countries, close to 40 to 50 percent of retinoblastoma patients develop metastatic disease."

Academy spokesperson William Mieler, MD, said, "This study, along with comparable studies conducted by Drs. Dunkel and Grabowski, provides encouraging evidence that a successful approach to treating this advanced, devastating disease is close at hand. Once the protocol is further established and tested on additional patients, we can hope to see further documentation of effective treatment for patients with advanced metastatic retinoblastoma."
-end-
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons--Eye M.D.s--with more than 27,000 members worldwide. For more information about eye health care, visit the Academy's partner Web site, the Medem Network, at http://www.medem.com/eyemd. To find an Eye M.D. in your area, visit the Academy's Web site at http://www.aao.org.

American Academy of Ophthalmology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.